For Healthcare Professionals

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

clipboard-pencil

About the study

A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Male or female, 12 years of age or older at the baseline visit. NOTE: Adolescent patients (at least 12 years old, but less than 18 years) are eligible in the US or Canada only after DUPIXENT receives the respective country's regulatory approval for use in this age group.
  2. Initiating treatment with DUPIXENT® as standard-of-care for AD according to the country-specific prescribing information (Note: Participants will be screened when they received their initial prescription for DUPIXENT®).
  3. Willing and able to comply with study-related activities.
  4. Able to understand and complete study-related questionnaires.
  5. Provide signed informed consent or parental/legal guardian consent plus patient assent, where applicable. Key

EXCLUSION CRITERIA

  1. Patients who have a contraindication to the drug according to the country-specific prescribing information label.
  2. Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the patient from adequately completing the schedule of visits and assessments.
  3. Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day. NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 844-734-6643Email iconEmail Study Center

Study’s details


Contition

Dermatitis, Atopic

Age (in years)

12 - 200

Participants needed

858

Est. Completion Date

Mar 2027

Treatment type

Observational [Patient Registry]


Sponsor

Regeneron Pharmaceuticals

ClinicalTrials.gov identifier

NCT03428646

Study number

R668-AD-1762

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.